CFTR and cystic fibrosis: In conclusion, proposed SAHA-mediated CF-lung disease intervention can benefit from multiple mechanism of actions such as (1) an anti-inflammatory, (2) T-reg inducer and (3) ΔF508-CFTR corrector drug (Fig. 6).